

Table S1. Risk of bias assessment of the included DAA studies (using the Cochrane tool for risk of bias)

Study	Ascertainment of cirrhosis	Time since last imaging*	Ascertainment of SVR	Control group/comparator	Adjusted for potential confounders	Follow-up duration#	Assessment during f/u	Assessment of HCC event	Time interval between HCC and initiation of HCV therapy^	Data on initial HCC management
DAA recurrence studies										
Yang, 2016		?	+	+	-	?	+	+	?	+
Pol,		?	+	+	+	+	?	?	+	?
Pol, CO12,		?	+	+	+	+	+	+	-	+
Pol, CO23,		?	+	-	+	+	?	+	+	+
Zavaglia, 2017		+	+	-	+	+	?	?	+	+
Torres, 2016		?	+	-	+	+	?	?	+	+
Adhoue,		+	+	+	+	+	+	+	+	+
Petta, 2017		+	+	+	-	+	+	+	-	+
Minami, 2016		?	+	+	+	+	?	?	+	+
Reig, 2017		+	+	+	+	-	+	+	+	+
Huang, 2017		?	+	+	+	?	+	+	?	+
Ikedo, 2017		+	+	+	+	+	+	+	+	+
Cabibbo,		+	+	+	+	-	+	+	+	+
Kolly, 2017		+	+	-	+	+	+	+	+	+
Virlogeuz,		+	+	+	+	+	+	+	+	+
Sangiovanni,		+	+	-	+	+	+	?	+	-
Minami, 2017			+	-	+	+	+	+	+	+
Urabe, 2018			-	+	+	-	+	+	+	-
Lleo, 2018			+	-	+	+	+	+	+	+
DAA										
Romano, 2018	+	+	+	-	+	+	+	+		
Kobayashi,	+	-	+	+	+	+	+	+		
Cardoso, 2016	+	?	+	?	+	+	?	?		
Toyoda, 2016	+	-	+	+	+	+	?	?		
Mangia, 2016	-	+	+	-	+	+	+	+		
Innes, 2018	-	?	+	+	+	+	-	-		
Ji, 2017	?	?	+	+	+	+	?	?		
Korenaga,	-	+	+	+	+	+	+	+		
Calvaruso,	+	+	+	-	+	+	+	+		
Ravi, 2017	?	+	+	-	+	-	+	+		
Muir, 2018	+	+	+	-	+	+	+	+		
Sogni, CO13,	+	?	+	-	+	-	?	+		
Kanwal, 2017	?	-	+	-	+	+	-	-		

Ioannou, 2017	+	?	+	+	+	+	?	+		
Tachi, 2017	+	+	+	-	+	+	+	+		
Nagaoki, 2017	+	-	+	+	+	+	+	+		
Backus, 2017	+	-	+	-	+	+	-	-		
Kozbial, 2017	+	+	+	-	+	+	+	+		
Pascasio, 2017	+	-	+	+	+	+	+	+		
Belli, 2017	+	+	+	-	-	+	?	?		
nunez, 2017	+	+	+	-	-	+	?	+		
Li, 2018	+	+	+	+	+	+	-	-		
Romano, 2017	+	+	+	+	+	+	+	+		
Kondili, 2017	+	?	+	+	+	+	+	?		
Sun Hong Yoo,	-	-	+	-	+	-	+	+		
Mangia, 2017	+	+	+	+	+	+	+	+		
Sangiovanni,	+	+	+	-	+	+	+	?		
Miyase, 2017	-	-	+	+	+	+	+	+		
kuftinec, 2017	+	+	+	-	+	+	+	+		
Lleo, 2018	+	+	+	-	+	+	+	+		
DAA occurrence &										
Conti, 2016	+	+	+	-	+	-	+	+	+	+
Lei-Zeng, 2016	+	?	+	-	+	+	+	+	?	+
Cheung, 2016	+	-	+	+	-	+	-	?	+	-
Issachar, 2017	-	?	+	-	?	+	+	+	?	?
Rinaldi, 2016	+	+	+	-	+	-	+	+	+	+
Menzaghi,	-	-	+	+	+	+	?	?	?	?
Douhara,	?	+	+	-	+	-	+	+	-	+
Cajella, 2017	+	-	+	-	+	-	?	+	+	-
Murcia, 2017	?	?	+	-	+	+	?	?	+	+
Fangazio,	?	+	+	-	+	-	+	+	-	-
Donato, 2017	+	?	+	+	+	+	+	+	?	+
Bielen, 2017	+	+	+	+	+	-	+	+	+	+
Degasperi,	+	+	+	-	-	+	+	+	-	-
Ogawa, 2017	+	?	+	-	+	+	+	?		
Ponziani, 2017	+	-	+	-	+	+	+	+	-	-
Sterling, 2018	+	+	+	-	+	-	+	+	-	-

+ : low risk of bias; ? : unclear risk of bias; - : high risk of bias; *: if the included subjects had undergone imaging which could assess for HCC within six months of starting treatment, the study was considered low risk for bias; #: studies with follow-up periods of one year or greater were considered low risk for bias; ^: studies with at least a six month interval between initial HCC curative treatment and initiation of HCV treatment were considered low risk for bias; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; DAA: direct-acting antiviral; IFN: interferon

Table S2. Risk of bias assessment of the included IFN studies (using the Cochrane tool for risk of bias)

Study	Ascertainment of cirrhosis	Time since last imaging	Ascertainment of SVR	Control group/comparator	Adjusted for potential confounders	Follow-up duration	Assessment during follow-up	Assessment of HCC event	Time interval between HCC and initiation of HCV therapy	Data on initial HCC management
IFN Recurrence Studies										
Hagihara, 2011			+	+	+	+	+	+	+	+
Kanogawa, 2015			+	+	+	+	+	+	?	+
Kunimoto, 2016			+	+	+	+	+	+	?	+
Jeong, 2007			+	+	+	+	+	+	+	+
Saito, 2014			+	+	+	+	+	+	+	+
Sanefuji, 2009			+	+	+	+	+	+	+	+
Minami, 2016			+	+	+	+	?	?	+	+
Petta, 2017			+	+	+	+	+	+	-	+
Bruno 2017			+	+	+	+	+	-	-	+
Hsu, 2013			-	+	+	+	+	+	-	+
Urabe, 2017			-	+	+	+	+	?	+	-
Kudo, 2007			-	+	+	+	+	+	-	+
Mazzaferro, 2006			+	+	+	+	+	+	-	+
Tanimoto, 2012			+	+	+	+	+	+	-	+
Shirtatori, 2003			+	+	+	+	+	+	-	+
Kubo, 2001			+	+	+	+	+	+	-	+
IFN										

Occurrence Studies										
Miyase, 2017	-	-	+	+	+	?	+	+		
Yamashita, 2014	+	+	+	-	+	+	+	+		
Ogawa, 2013	+	-	+	-	+	+	+	+		
van der Meer, 2017	+	-	+	-	+	+	?	+		
Bruno, 2009	+	+	+	+	+	+	+	+		
Mallet, 2008	+	+	+	+	+	+	+	+		
Cardoso, 2010	+	?	+	+	+	+	+	+		
Yu, 2006	+	+	+	+	+	+	+	+		
Hung, 2006	+	+	+	+	+	+	+	+		
Morgan, 2010	+	+	+	+	+	+	+	+		
Aleman, 2013	+	?	+	+	+	+	+	+		
Cheinquer, 2010	+	+	+	+	+	+	+	+		
Moon, 2015	+	+	+	+	+	+	+	+		
Fernandez-Rodríguez, 2010	+	+	+	+	+	+	+	+		
Janjua, 2016	+	?	+	+	+	+	?	+		
Rutter, 2016	+	+	+	+	+	+	+	+		
Velosa, 2011	+	+	+	+	+	+	+	+		
Nahon, 2017	+	+	+	+	+	+	+	+		
Di Marco, 2016	+	+	+	+	+	+	+	+		
Trapero-Marguán, 2011	+	-	+	-	+	+	+	+		
El Braks, 2007	+	+	+	-	+	+	+	+		
van der Meer, 2012	+	-	+	-	+	+	+	+		
El-Serag, 2016	+	-	+	-	+	+	+	?		
Kobayashi, 2017	+	-	+	+	+	+	+	+		
Toyoda, 2016	+	-	+	+	+	+	?	?		
Innes, 2017	-	?	+	+	+	+	-	-		
Ioannou, 2017	+	?	+	+	+	+	?	+		

Nagaoki, 2017	+	-	+	+	+	+	+	+		
Li, 2018	+	+	+	+	+	+	-	-		
Miyase, 2017	-	-	+	+	+	+	+	+		
Hsu, 2013	-	-	-	+	+	+	+	+		
Cardoso, 2016	+	?	+	?	+	+	?	?		

+ : low risk of bias; ? : unclear risk of bias; - : high risk of bias; *: if the included subjects had undergone imaging which could assess for HCC within six months of starting treatment, the study was considered low risk for bias; #: studies with follow-up periods of one year or greater were considered low risk for bias; ^: studies with at least a six month interval between initial HCC curative treatment and initiation of HCV treatment were considered low risk for bias; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; DAA= direct-acting antiviral; IFN= interferon